Unique Clinical and Histological Features of Placental Mesenchymal Dysplasia Complicated by Severe Preeclampsia in the Midtrimester

Abstract

Detailed clinical and pathological features of placental mesenchymal dysplasia (PMD) complicated by preeclampsia (PE) are unknown. A 39-year-old nulliparous woman was referred at 19 weeks gestation. Ultrasound examination identified a fetus with severe growth restriction (−2.8 SD) and a markedly thickened placenta with many cystic structures suggestive of PMD. At 21 weeks, the patient developed severe hypertension (180/95 mm Hg) with marked proteinuria and an elevated serum soluble fms-like tyrosine-kinase-1 (sFlt-1) level (47,000 pg/L). The pregnancy was terminated to protect maternal health. Placental weight was 450 g and no histopathological findings of either proliferation or dysplasia were observed in the trophoblast. Villous chromosome examination revealed a 46XX karyotype, consistent with the diagnosis of PMD. In addition to the pathological findings of vascular endothelial dysfunction characteristic of the placenta in PE cases, enhanced expression of sFlt-1 in the syncytiotrophoblast of the enlarged villi was confirmed by immunohistochemistry as a novel finding in this condition. Monitoring of the serum sFlt-1 value is suggested to be a useful predictor of the pathological change associated with extremely early severe PE in PMD cases.

Keywords

placental mesenchymal dysplasia - sFlt-1 - preeclampsia - intrauterine growth restriction

• References

• 1 Moscoso G, Jauniaux E, Hustin J. Placental vascular anomaly with diffuse mesenchymal stem villous hyperplasia. A new clinico-pathological entity?. Pathol Res Pract 1991; 187 (2-3): 324-328
• 2 Toru HS, Aytekin EÇ, Sanhal CY. , et al. We can diagnose it if we consider it. Diagnostic pitfall for placenta: placental mesenchymal dysplasia. Turk Patoloji Derg 2018; 34 (01) 100-103
• 3 Pham T, Steele J, Stayboldt C, Chan L, Benirschke K. Placental mesenchymal dysplasia is associated with high rates of intrauterine growth restriction and fetal demise: a report of 11 new cases and a review of the literature. Am J Clin Pathol 2006; 126 (01) 67-78
• 4 Takayama M, Soma H, Yaguchi S. , et al. Abnormally large placenta associated with Beckwith-Wiedemann syndrome. Gynecol Obstet Invest 1986; 22 (03) 165-168
• 5 Kuwabara Y, Shima Y, Araki T, Shin S. Mesenchymal stem villous hyperplasia of the placenta and fetal growth restriction. Obstet Gynecol 2001; 98 (5 Pt 2): 940-943
• 6 Surti U, Hill LM, Dunn J, Prosen T, Hoffner L. Twin pregnancy with a chimeric androgenetic and biparental placenta in one twin displaying placental mesenchymal dysplasia phenotype. Prenat Diagn 2005; 25 (11) 1048-1056
• 7 Duffett L, Rodger M. LMWH to prevent placenta-mediated pregnancy complications: an update. Br J Haematol 2015; 168 (05) 619-638
• 8 Na ED, Lee KJ, Kim M-J, Yi H-J, Kim J-Y. Placental mesenchymal dysplasia associated with severe preeclampsia: a case report. Korean J Obstet Gynecol 2011; 54: 459-463
• 9 Gu Y, Lewis DF, Wang Y. Placental productions and expressions of soluble endoglin, soluble fms-like tyrosine kinase receptor-1, and placental growth factor in normal and preeclamptic pregnancies. J Clin Endocrinol Metab 2008; 93 (01) 260-266
• 10 Levine RJ, Lam C, Qian C. , et al; CPEP Study Group. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 2006; 355 (10) 992-1005